The article presents an interview with Gregory R. Chiklis, president of ZeptoMetrix Corp.'s (ZMC) Research and Development about the biosafety laboratory and seroconversion, the nature of the work of the company and how that work plays a role in finding solutions to influenza threats. He describes several viruses that ZMC currently handles. INSETS: Better patient management;Automating next-gen rapid flu tests;Flu + pneumonia = complications;ID circulating pathogens